Innovative Therapies for Rheumatic and Skin Diseases

Notice Number: NOT-AR-05-002

Key Dates
Release Date: January 6, 2005

Issued by
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), (

This announces the availability of a Broad Agency Announcement (BAA), which describes in general terms a research topic and outlines proposal preparation requirements. The purpose of this BAA is to solicit proposals to carry out pilot/feasibility (open label, phase I/II) clinical studies to establish the safety and gather enough preliminary evidence of efficacy of new and innovative therapeutic approaches to rheumatic and skin diseases and to design and implement basic or clinical research ancillary projects linked to the clinical trial protocol. The goal of this initiative is to accelerate the application of new drugs, biologicals and other non-behavioral interventions for the short and long term management of symptoms, signs, systemic and structural changes in patients with established rheumatic and skin diseases and for the development of strategies for prevention of disease onset, progression or structural damage to target organs in patients at high risk. New and emerging agents for the treatment of lupus, rheumatoid arthritis, scleroderma, myositis, Sjogren's and other rheumatic diseases are included. In the skin diseases area, inflammatory, autoimmune, and genetic skin diseases are included as are small trials for innovative therapies on wound healing.

It is anticipated that two cost reimbursement contract awards will be made for a maximum period of five years beginning on or about September 30, 2005. The solicitation NIH-NIAMS-BAA-05-01 will be available electronically on or about January 14, 2005 and may be accessed through the Internet at the following address: Proposals will be due on or about March 25, 2005. Offerors are responsible for downloading their own copy of the solicitation and amendments and for routinely checking the Internet site for any possible solicitation amendments that may be issued by the Government. All responsible sources may submit proposals which will be considered by the Government. The North American Industrial Classification System (NAICS) code for this acquisition is 541710. This advertisement does not commit the Government to award a contract.


Inquiries may be directed to:

Eileen Webster-Cissel
Chief Contracting Officer
Contracts Management Branch, EP
National Institute of Arthritis and
Musculoskeletal and Skin Diseases
6705 Democracy Boulevard, Suite 800, MSC 4872
Bethesda, Maryland 20892-4872
Telephone: 301-594-2543
FAX: 301-480-5996

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

H H S Department of Health
and Human Services

  N I H National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892